Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 1.4%

Inhibikase Therapeutics, Inc. (NYSE:IKT) traded down 1.4% on Thursday . The company traded as low as $2.04 and last traded at $2.10. 27,598 shares changed hands during trading, a decline of 78% from the average session volume of 126,159 shares. The stock had previously closed at $2.13.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Inhibikase Therapeutics in a report on Tuesday, March 5th.

Inhibikase Therapeutics Trading Down 1.4 %

The stock has a 50 day simple moving average of $2.24 and a 200 day simple moving average of $1.67. The firm has a market capitalization of $13.61 million, a PE ratio of -0.59 and a beta of 1.19.

Inhibikase Therapeutics (NYSE:IKT) last announced its quarterly earnings results on Wednesday, March 27th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. Inhibikase Therapeutics had a negative return on equity of 107.54% and a negative net margin of 5,886.15%. As a group, equities analysts anticipate that Inhibikase Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Institutional Investors Weigh In On Inhibikase Therapeutics

A number of large investors have recently made changes to their positions in the business. Barclays PLC bought a new stake in shares of Inhibikase Therapeutics in the 2nd quarter worth approximately $41,000. Armistice Capital LLC bought a new stake in shares of Inhibikase Therapeutics during the first quarter valued at approximately $1,947,000. Blair William & Co. IL boosted its position in shares of Inhibikase Therapeutics by 20.5% during the first quarter. Blair William & Co. IL now owns 276,000 shares of the company’s stock valued at $181,000 after purchasing an additional 47,000 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Inhibikase Therapeutics by 17.7% during the second quarter. Renaissance Technologies LLC now owns 221,900 shares of the company’s stock valued at $165,000 after purchasing an additional 33,431 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Inhibikase Therapeutics by 10.7% during the first quarter. Vanguard Group Inc. now owns 530,098 shares of the company’s stock valued at $785,000 after purchasing an additional 51,394 shares in the last quarter. 3.81% of the stock is currently owned by institutional investors.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.